유전성 암검사 시장 : 암 유형별, 검사 유형별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global hereditary cancer testing market was valued at $3,510.29 million in 2021, and is projected to reach $10,087.49 million by 2031, registering a CAGR of 11.6% from 2022 to 2031.

Genetic testing helps estimate the chance of developing cancer in the lifetime. This can be done by searching for specific changes in the genes, chromosomes, or proteins  called mutations. Genetic tests are available for some types of cancer which include breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, kidney cancer and stomach cancer. People who are concerned about whether their family history puts them at risk for cancer should consult with a genetic counselor. The features of personal or family medical history of a person that particularly is in combination, may suggest a hereditary cancer syndrome such as the cancer was diagnosed at an unusually young age or several different types of cancer occurred in the same person. Moreover, hereditary cancer testing can also verify the type of cancer inherited in the person. If a person in the family has already been found to have an inherited cancer susceptibility syndrome, then any family members who could have inherited the variant should consider genetic testing. It is because knowing about the risks may help to prevent a future cancer.

The growth of the hereditary cancer testing market is driven by rise in geriatric population and increase in incidence of cancer across the globe, and surge in the government expenditure on healthcare. Moreover, increase in awareness regarding the hereditary cancer testing and favorable reimbursement policies contribute toward the growth of the market. However, lack of skilled professionals and high cost of the tests are expected to hinder the growth of the market. Conversely, high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The hereditary cancer testing market is segmented on the basis of cancer type, test type, end user, and region. On the basis of cancer type, the market is categorized into breast cancer, gastric cancer, ovarian cancer, prostate cancer, colorectal cancer, other cancers. On the basis of test type, the market is classified into predictive testing and diagnostic testing. On the basis of end user, the market is classified into diagnostic centers, hospitals and clinics. Furthermore, the hospitals segment is sub-classified by type as private and public. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hereditary cancer testing market analysis from 2021 to 2031 to identify the prevailing hereditary cancer testing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hereditary cancer testing market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hereditary cancer testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Cancer Type

• Breast Cancer
• Gastric Cancer
• Ovarian Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancers

By Test Type

• Predictive Testing
• Diagnostic Testing

By End User

• Diagnostic Centers
• Hospitals
  • Type
  • Private
  • Public
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • CSL Ltd.
  • Danaher Corporation
  • EUROFINS SCIENTIFIC
  • F. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Breast Cancer
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Gastric Cancer
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Ovarian Cancer
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country
• 4.5 Prostate Cancer
  • 4.5.1 Key market trends, growth factors and opportunities
  • 4.5.2 Market size and forecast, by region
  • 4.5.3 Market analysis by country
• 4.6 Colorectal Cancer
  • 4.6.1 Key market trends, growth factors and opportunities
  • 4.6.2 Market size and forecast, by region
  • 4.6.3 Market analysis by country
• 4.7 Other Cancers
  • 4.7.1 Key market trends, growth factors and opportunities
  • 4.7.2 Market size and forecast, by region
  • 4.7.3 Market analysis by country

CHAPTER 5: HEREDITARY CANCER TESTING MARKET, BY TEST TYPE

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Predictive Testing
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Diagnostic Testing
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country

CHAPTER 6: HEREDITARY CANCER TESTING MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Diagnostic Centers
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Hospitals
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
  • 6.3.4 Hospitals Hereditary Cancer Testing Market by Type
    • 6.3.4.1 Private Market size and forecast, by region
    • 6.3.4.2 Public Market size and forecast, by region
• 6.4 Clinics
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: HEREDITARY CANCER TESTING MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Cancer Type
  • 7.2.3 North America Market size and forecast, by Test Type
  • 7.2.4 North America Market size and forecast, by End User
    • 7.2.4.1 North America Hospitals Hereditary Cancer Testing Market by Type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Cancer Type
    • 7.2.5.1.2 Market size and forecast, by Test Type
    • 7.2.5.1.3 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Cancer Type
    • 7.2.5.2.2 Market size and forecast, by Test Type
    • 7.2.5.2.3 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Cancer Type
    • 7.2.5.3.2 Market size and forecast, by Test Type
    • 7.2.5.3.3 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Cancer Type
  • 7.3.3 Europe Market size and forecast, by Test Type
  • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.4.1 Europe Hospitals Hereditary Cancer Testing Market by Type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Cancer Type
    • 7.3.5.1.2 Market size and forecast, by Test Type
    • 7.3.5.1.3 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Cancer Type
    • 7.3.5.2.2 Market size and forecast, by Test Type
    • 7.3.5.2.3 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Cancer Type
    • 7.3.5.3.2 Market size and forecast, by Test Type
    • 7.3.5.3.3 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Cancer Type
    • 7.3.5.4.2 Market size and forecast, by Test Type
    • 7.3.5.4.3 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Cancer Type
    • 7.3.5.5.2 Market size and forecast, by Test Type
    • 7.3.5.5.3 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Cancer Type
    • 7.3.5.6.2 Market size and forecast, by Test Type
    • 7.3.5.6.3 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Cancer Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Test Type
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.4.1 Asia-Pacific Hospitals Hereditary Cancer Testing Market by Type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Cancer Type
    • 7.4.5.1.2 Market size and forecast, by Test Type
    • 7.4.5.1.3 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Cancer Type
    • 7.4.5.2.2 Market size and forecast, by Test Type
    • 7.4.5.2.3 Market size and forecast, by End User
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Cancer Type
    • 7.4.5.3.2 Market size and forecast, by Test Type
    • 7.4.5.3.3 Market size and forecast, by End User
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Cancer Type
    • 7.4.5.4.2 Market size and forecast, by Test Type
    • 7.4.5.4.3 Market size and forecast, by End User
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Cancer Type
    • 7.4.5.5.2 Market size and forecast, by Test Type
    • 7.4.5.5.3 Market size and forecast, by End User
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Cancer Type
    • 7.4.5.6.2 Market size and forecast, by Test Type
    • 7.4.5.6.3 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Cancer Type
  • 7.5.3 LAMEA Market size and forecast, by Test Type
  • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.4.1 LAMEA Hospitals Hereditary Cancer Testing Market by Type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Cancer Type
    • 7.5.5.1.2 Market size and forecast, by Test Type
    • 7.5.5.1.3 Market size and forecast, by End User
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Cancer Type
    • 7.5.5.2.2 Market size and forecast, by Test Type
    • 7.5.5.2.3 Market size and forecast, by End User
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Cancer Type
    • 7.5.5.3.2 Market size and forecast, by Test Type
    • 7.5.5.3.3 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Cancer Type
    • 7.5.5.4.2 Market size and forecast, by Test Type
    • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Abbott Laboratories
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Bio-Rad Laboratories, Inc.
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 CSL Ltd.
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Danaher Corporation
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 EUROFINS SCIENTIFIC
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 F. HOFFMANN-LA ROCHE LTD
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Illumina, Inc.
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Myriad Genetics, Inc.
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Qiagen NV
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Thermo Fisher Scientific, Inc.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments